NASDAQ:INMB - INmune Bio Stock Price, Forecast & News

INmune Bio's stock was trading at $4.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INMB shares have decreased by 39.6% and is now trading at $2.90. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for INmune Bio.

INmune Bio is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for INmune Bio.

INmune Bio Inc (NASDAQ:INMB) posted its quarterly earnings data on Wednesday, March, 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.03. View INmune Bio's earnings history.

3 analysts have issued 12-month price targets for INmune Bio's shares. Their forecasts range from $8.00 to $13.00. On average, they expect INmune Bio's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 290.8% from the stock's current price. View analysts' price targets for INmune Bio.

Headlines about INMB stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. INmune Bio earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutINmune Bio.

INmune Bio saw a decrease in short interest in March. As of March 13th, there was short interest totaling 3,100 shares, a decrease of 74.6% from the February 27th total of 12,200 shares. Based on an average daily volume of 98,500 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the shares of the company are short sold. View INmune Bio's Current Options Chain.

Some companies that are related to INmune Bio include Fennec Pharmaceuticals (FENC), Cidara Therapeutics (CDTX), Erytech Pharma (ERYP), Vaxart (VXRT), Gamida Cell (GMDA), Champions Oncology (CSBR), Axcella Health (AXLA), Neon Therapeutics (NTGN), Applied Genetic Technologies (AGTC), AIM ImmunoTech (AIM), Pluristem Therapeutics (PSTI), Acorda Therapeutics (ACOR), Surface Oncology (SURF), BIONDVAX PHARMA/S (BVXV) and Polarityte (PTE).

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Canadian Solar (CSIQ), Spectrum Pharmaceuticals (SPPI), Axon Enterprise (AAXN), Ambarella (AMBA), AbbVie (ABBV), General Motors (GM), IBM (IBM), Main Street Capital (MAIN), AT&T (T) and Verizon Communications (VZ).

INmune Bio trades on the NASDAQ under the ticker symbol "INMB."

Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INMB stock can currently be purchased for approximately $2.90.

INmune Bio has a market capitalization of $31.18 million. The company earns $-7,680,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. INmune Bio employs 3 workers across the globe. View additional information about INmune Bio.

The official website for INmune Bio is http://www.inmunebio.com/.

INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company can be reached via phone at 858-964-3720 or via email at [email protected]